Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imprime PGG and Pembrolizumab in HR+/HER2- Metastatic Breast Cancer
NCT05159778Phase 2Completed
- Sponsor
- HiberCell
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of odetiglucan in breast cancer, sponsored by HiberCell. Started Nov 2021; status: completed.
02
Drugs
odetiglucan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05159778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159778.